베타-3 아드레날린 수용체

ADRB3
사용 가능한 구조물
PDB	직교 검색: PDBe RCSB
PDB ID 코드 목록
	2CDW
식별자
별칭	ADRB3, 베타3AR, Adrenoceptor 베타 3
외부 ID	OMIM: 109691 MGI: 87939 HomoloGene: 37250 GeneCard: ADRB3
유전자 위치(인간)
쳇.	8번 염색체(인간)
끝	37,966,599 bp
유전자 위치(마우스)
쳇.	8번 염색체(쥐)
끝	27,250,616 bp
RNA 표현 패턴
	표현된 상단
	비뇨기 방광; ; 난소의; ; 펀두스;
	추가 참조 표현식 데이터
	; ;
	추가 참조 표현식 데이터
유전자 온톨로지
분자함수	베타 아드레날린 수용체 활성; G 단백질 결합 수용체 활성; 에피네프린 제본; 단백질 호모디메르화 활동; 베타3-아드레날린 수용체 활성; 노레피네프린 제본; 베타-3 아드레날린 수용체 결합; 신호 변환기 활동; 아드레날린 수용체 활성; GO:0001948 단백질 결합;
셀룰러 컴포넌트	막의 적분 성분; 막으로 막다; 수용체 복합체; 플라즈마 막; 플라스마 막의 적분 성분; 핵의;
생물학적 과정	아데닐레이트 사이클라아제 활성화 G 단백질 결합 수용체 신호 경로; 식생활.; 아데닐레이트 사이클라아제-변형 G 단백질 결합 수용체 신호 경로; 항생제에 대한 반응; 다세포 유기체 성장에 대한 부정적인 규제; 세포 세포 신호; G 단백질 결합 수용체 신호 경로, 주기적 뉴클레오티드 두 번째 메신저와 결합; 노화; 수용체 매개 내포증; 전구 대사물과 에너지의 생성; 아데닐레이트 사이클라아제 활성화; 식이요법으로 인한 열생식; 전신 동맥 혈압 조절에 관여하는 노레피네프린-에피네프린 매개 혈관 절제술; 아데닐레이트 사이클라제-아드레날린 아드레날린 수용체 신호 경로; 열 발생; 갈색 지방 세포 분화; 추위에 대한 반응; 에너지 예비 대사 과정; 온도 동점; 아레스틴에 의한 G단백질 결합 수용체 신호 경로의 감응화; MAPK 계단식 규제; 신호 전달; 탄수화물 대사 과정; G 단백질 결합 수용체 신호 경로; 냉간 유도 열생식에 대한 양성 조절;
	출처:아미고 / 퀵고
직교체
	155
	11556
	ENSG00000188778
	ENSMUSG00000031489
	P13945
	P25962
	NM_000025
	NM_013462
	NP_000016
	NP_038490
	위키다타
인간 보기/편집	마우스 보기/편집

ADRB3로도 알려진 베타-3 아드레날린 수용체(β-아드레노셉터₃)는 베타 아드레날린 수용체로서, 인간의 유전자 인코딩을 나타내기도 한다.^[5]

함수

β₃ 수용체의 작용은 다음을 포함한다.

지방 조직의 지방분해 강화.^[6]
골격근에서의^[7] 열유전증

주로 지방조직에 위치하며, 지방분해와 열생식 조절에 관여한다.일부 β₃ 작용제들은 동물 연구에서 항스트레스 효과를 입증하여 그것이 중추신경계(CNS)에서도 역할을 한다는 것을 시사했다. β₃ 수용체는 담낭, 비뇨기 방광, 갈색 지방 조직에서 발견된다.담낭생리학에서 그들의 역할은 알 수 없으나, 갈색 지방에서는 지용성분해와 열생식에 역할을 하는 것으로 생각된다.방광에서는 방광의 이완과 배뇨 예방을 일으키는 것으로 생각된다.^[8]

작용기전

베타 아드레날린 수용체는 G형식의_s G단백질의 작용을 통해 에피네프린과 노레피네프린 유도 아데닐산 사이클라아제 활성화에 관여한다.^[5]

리간즈

고민자

아미베그론(SR-58611A)^[9]^[10]
BRL-37344^[11]
CL-316,243^[12]
L-742,791^[13]
L-796,568^[14]
LY-368,842
미라베그론(YM-178)은 일본, 미국, 영국, 캐나다, 중국, 인도에서 과민성 방광 치료를 승인했다.^[15]
네비볼롤^[16] 선택 베타(1)-차단기 및 베타(3)-아곤기.
로40-2148번길
솔라베그론(^[17]GW-427,353)
비베그론 (MK-4618)^[18]

반목자

L-748,328^[13]
L-748,337^[13]
SR 59230A는 선택적 β₃ 길항제인^[19] 것으로 생각되었으나 나중에 α₁ 수용체의 길항제인 것으로도 밝혀졌다.^[20]

상호작용

베타-3 아드레날린 수용체가 Src와 상호작용하는 것으로 나타났다.^[21]

참고 항목

기타 아드레날린 수용체

참조

^ ^a ^b ^c GRCh38: 앙상블 릴리스 89: ENSG00000188778 - 앙상블, 2017년 5월
^ ^a ^b ^c GRCm38: 앙상블 릴리스 89: ENSMUSG000031489 - 앙상블, 2017년 5월
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ ^a ^b "Entrez Gene: ADRB3 adrenergic, beta-3-, receptor".
^ Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M (September 2005). "Combined effects of oleoyl-estrone and a β₃-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats". Life Sciences. 77 (16): 2051–8. doi:10.1016/j.lfs.2005.04.008. PMID 15935402.
^ Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. 163페이지
^ Sawa M, Harada H (2006). "Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists". Current Medicinal Chemistry. 13 (1): 25–37. doi:10.2174/092986706775198006. PMID 16457637.
^ Consoli D, Leggio GM, Mazzola C, Micale V, Drago F (November 2007). "Behavioral effects of the β₃ adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?". European Journal of Pharmacology. 573 (1–3): 139–47. doi:10.1016/j.ejphar.2007.06.048. PMID 17669397.
^ Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective β₃ adrenoceptor agonist amibegron in an animal model of depression". Pharmacology Biochemistry and Behavior. 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519. S2CID 35026036.
^ Mukaida S, Sato M, Öberg AI, Dehvari N, Olsen JM, Kocan M, et al. (May 2019). "BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 316 (5): R666–R677. doi:10.1152/ajpregu.00285.2018. PMID 30892909.
^ Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y (2008). "The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice". European Journal of Pharmacology. 584 (1): 202–6. doi:10.1016/j.ejphar.2008.01.028. PMID 18304529.
^ ^a ^b ^c Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE (August 1999). "Potent and selective human beta(3)-adrenergic receptor antagonists". The Journal of Pharmacology and Experimental Therapeutics. 290 (2): 649–55. PMID 10411574.
^ Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, Astrup A (2002). "Effect of a 28-d treatment with L-796568, a novel β₃-adrenergic receptor agonist, on energy expenditure and body composition in obese men". The American Journal of Clinical Nutrition. 76 (4): 780–8. doi:10.1093/ajcn/76.4.780. PMID 12324291.
^ Gras J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of Today. 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
^ Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C (2009). "Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart". J Am Coll Cardiol. 53 (17): 1532–8. doi:10.1016/j.jacc.2008.11.057. PMID 19389564.
^ Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP (October 2007). "GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 202–9. doi:10.1124/jpet.107.125757. PMID 17626794. S2CID 19281697.
^ Edmondson SD, Zhu C, Kar N-F, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen D-M, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE (January 2016). "Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder". Journal of Medicinal Chemistry. 59 (2): 609–23. doi:10.1021/acs.jmedchem.5b01372. PMID 26709102.
^ Nisoli E, Tonello C, Landi M, Carruba MO (1996). "Functional studies of the first selective β₃-adrenergic receptor antagonist SR 59230A in rat brown adipocytes". Mol. Pharmacol. 49 (1): 7–14. PMID 8569714.
^ Bexis S, Docherty JR (April 2009). "Role of α1- and β3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse". British Journal of Pharmacology. 158 (1): 259–66. doi:10.1111/j.1476-5381.2009.00186.x. PMC 2795232. PMID 19422394.
^ Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, Lefkowitz RJ, Collins S (2000). "Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation". J. Biol. Chem. 275 (49): 38131–4. doi:10.1074/jbc.C000592200. PMID 11013230.

추가 읽기

Granneman JG, Lahners KN, Rao DD (1993). "Rodent and human beta 3-adrenergic receptor genes contain an intron within the protein-coding block". Mol. Pharmacol. 42 (6): 964–70. PMID 1336117.
Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ (1991). "Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes". EMBO J. 10 (12): 3721–7. doi:10.1002/j.1460-2075.1991.tb04940.x. PMC 453106. PMID 1718744.
Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989). "Molecular characterization of the human beta 3-adrenergic receptor". Science. 245 (4922): 1118–21. Bibcode:1989Sci...245.1118E. doi:10.1126/science.2570461. PMID 2570461.
Guan XM, Amend A, Strader CD (1995). "Determination of structural domains for G protein coupling and ligand binding in beta 3-adrenergic receptor". Mol. Pharmacol. 48 (3): 492–8. PMID 7565630.
Rodriguez M, Carillon C, Coquerel A, Le Fur G, Ferrara P, Caput D, Shire D (1995). "Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain". Brain Res. Mol. Brain Res. 29 (2): 369–75. doi:10.1016/0169-328X(94)00274-I. PMID 7609625.
Clément K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD (1995). "Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity". N. Engl. J. Med. 333 (6): 352–4. doi:10.1056/NEJM199508103330605. PMID 7609752.
Dib A, Adélaïde J, Chaffanet M, Imbert A, Le Paslier D, Jacquemier J, Gaudray P, Theillet C, Birnbaum D, Pébusque MJ (1995). "Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma". Oncogene. 10 (5): 995–1001. PMID 7898940.
Mahmoudian M (1994). "The complex of human Gs protein with the beta 3 adrenergic receptor: a computer-aided molecular modeling study". Journal of Molecular Graphics. 12 (1): 22–8, 34. doi:10.1016/0263-7855(94)80004-9. PMID 8011597.
Wilkie TM, Chen Y, Gilbert DJ, Moore KJ, Yu L, Simon MI, Copeland NG, Jenkins NA (1994). "Identification, chromosomal location, and genome organization of mammalian G-protein-coupled receptors". Genomics. 18 (2): 175–84. doi:10.1006/geno.1993.1452. PMID 8288218.
Krief S, Lönnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, Strosberg AD, Ricquier D, Emorine LJ (1993). "Tissue distribution of beta 3-adrenergic receptor mRNA in man". J. Clin. Invest. 91 (1): 344–9. doi:10.1172/JCI116191. PMC 330032. PMID 8380813.
van Spronsen A, Nahmias C, Krief S, Briend-Sutren MM, Strosberg AD, Emorine LJ (1993). "The promoter and intron/exon structure of the human and mouse beta 3-adrenergic-receptor genes". Eur. J. Biochem. 213 (3): 1117–24. doi:10.1111/j.1432-1033.1993.tb17861.x. PMID 8389293.
Lelias JM, Kaghad M, Rodriguez M, Chalon P, Bonnin J, Dupre I, Delpech B, Bensaid M, LeFur G, Ferrara P (1993). "Molecular cloning of a human beta 3-adrenergic receptor cDNA". FEBS Lett. 324 (2): 127–30. doi:10.1016/0014-5793(93)81377-C. PMID 8389717. S2CID 84702667.
Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD (1996). "Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant". Endocrinology. 137 (6): 2638–41. doi:10.1210/en.137.6.2638. PMID 8641219.
Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T (1996). "Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain". Diabetologia. 39 (3): 349–52. doi:10.1007/BF00418352. PMID 8721782. S2CID 24270803.
Higashi K, Ishikawa T, Ito T, Yonemura A, Shige H, Nakamura H (1997). "Association of a genetic variation in the beta 3-adrenergic receptor gene with coronary heart disease among Japanese". Biochem. Biophys. Res. Commun. 232 (3): 728–30. doi:10.1006/bbrc.1997.6339. PMID 9126344.
Hoffstedt J, Poirier O, Thörne A, Lönnqvist F, Herrmann SM, Cambien F, Arner P (1999). "Polymorphism of the human beta3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function". Diabetes. 48 (1): 203–5. doi:10.2337/diabetes.48.1.203. PMID 9892244.
Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A (1999). "Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis". Nat. Genet. 22 (3): 239–47. doi:10.1038/10297. PMID 10391210. S2CID 4636523.
Kimura K, Sasaki N, Asano A, Mizukami J, Kayahashi S, Kawada T, Fushiki T, Morimatsu M, Yoshida T, Saito M (2000). "Mutated human beta3-adrenergic receptor (Trp64Arg) lowers the response to beta3-adrenergic agonists in transfected 3T3-L1 preadipocytes". Horm. Metab. Res. 32 (3): 91–6. doi:10.1055/s-2007-978597. PMID 10786926.
Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, Lefkowitz RJ, Collins S (2001). "Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation". J. Biol. Chem. 275 (49): 38131–4. doi:10.1074/jbc.C000592200. PMID 11013230.
Russell ST, Hirai K, Tisdale MJ (2002). "Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor". Br. J. Cancer. 86 (3): 424–8. doi:10.1038/sj.bjc.6600086. PMC 2375201. PMID 11875710.

외부 링크

"β₃-adrenoceptor". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
UCSC 게놈 브라우저의 인간 ADRB3 게놈 위치 및 ADRB3 유전자 세부 정보 페이지.

[refGRCh38Ensembl-1] GRCh38: 앙상블 릴리스 89: ENSG00000188778 - 앙상블, 2017년 5월

[refGRCm38Ensembl-2] GRCm38: 앙상블 릴리스 89: ENSMUSG000031489 - 앙상블, 2017년 5월

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[entrez-5] "Entrez Gene: ADRB3 adrenergic, beta-3-, receptor".

[pmid15935402-6] Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M (September 2005). "Combined effects of oleoyl-estrone and a β₃-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats". Life Sciences. 77 (16): 2051–8. doi:10.1016/j.lfs.2005.04.008. PMID 15935402.

[Rang163-7] Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. 163페이지

[pmid16457637-8] Sawa M, Harada H (2006). "Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists". Current Medicinal Chemistry. 13 (1): 25–37. doi:10.2174/092986706775198006. PMID 16457637.

[pmid17669397-9] Consoli D, Leggio GM, Mazzola C, Micale V, Drago F (November 2007). "Behavioral effects of the β₃ adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?". European Journal of Pharmacology. 573 (1–3): 139–47. doi:10.1016/j.ejphar.2007.06.048. PMID 17669397.

[pmid18358519-10] Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective β₃ adrenoceptor agonist amibegron in an animal model of depression". Pharmacology Biochemistry and Behavior. 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519. S2CID 35026036.

[pmid30892909-11] Mukaida S, Sato M, Öberg AI, Dehvari N, Olsen JM, Kocan M, et al. (May 2019). "BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 316 (5): R666–R677. doi:10.1152/ajpregu.00285.2018. PMID 30892909.

[12] Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y (2008). "The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice". European Journal of Pharmacology. 584 (1): 202–6. doi:10.1016/j.ejphar.2008.01.028. PMID 18304529.

[pmid10411574-13] Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE (August 1999). "Potent and selective human beta(3)-adrenergic receptor antagonists". The Journal of Pharmacology and Experimental Therapeutics. 290 (2): 649–55. PMID 10411574.

[pmid12324291-14] Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, Astrup A (2002). "Effect of a 28-d treatment with L-796568, a novel β₃-adrenergic receptor agonist, on energy expenditure and body composition in obese men". The American Journal of Clinical Nutrition. 76 (4): 780–8. doi:10.1093/ajcn/76.4.780. PMID 12324291.

[15] Gras J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of Today. 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.

[16] Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C (2009). "Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart". J Am Coll Cardiol. 53 (17): 1532–8. doi:10.1016/j.jacc.2008.11.057. PMID 19389564.

[pmid17626794-17] Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP (October 2007). "GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 202–9. doi:10.1124/jpet.107.125757. PMID 17626794. S2CID 19281697.

[pmid17626795-18] Edmondson SD, Zhu C, Kar N-F, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen D-M, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE (January 2016). "Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder". Journal of Medicinal Chemistry. 59 (2): 609–23. doi:10.1021/acs.jmedchem.5b01372. PMID 26709102.

[pmid8569714-19] Nisoli E, Tonello C, Landi M, Carruba MO (1996). "Functional studies of the first selective β₃-adrenergic receptor antagonist SR 59230A in rat brown adipocytes". Mol. Pharmacol. 49 (1): 7–14. PMID 8569714.

[pmid19422394-20] Bexis S, Docherty JR (April 2009). "Role of α1- and β3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse". British Journal of Pharmacology. 158 (1): 259–66. doi:10.1111/j.1476-5381.2009.00186.x. PMC 2795232. PMID 19422394.

[pmid11013230-21] Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, Lefkowitz RJ, Collins S (2000). "Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation". J. Biol. Chem. 275 (49): 38131–4. doi:10.1074/jbc.C000592200. PMID 11013230.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

Search